| Genetic and functional drivers of diffuse large B cell lymphoma A Reddy, J Zhang, NS Davis, AB Moffitt, CL Love, A Waldrop, S Leppa, ... Cell 171 (2), 481-494. e15, 2017 | 987 | 2017 |
| MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression … S Hu, ZY Xu-Monette, A Tzankov, T Green, L Wu, A Balasubramanyam, ... Blood, The Journal of the American Society of Hematology 121 (20), 4021-4031, 2013 | 802 | 2013 |
| Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study OA O'Connor, B Pro, L Pinter-Brown, N Bartlett, L Popplewell, B Coiffier, ... Journal of clinical oncology 29 (9), 1182-1189, 2011 | 690 | 2011 |
| The genetic landscape of mutations in Burkitt lymphoma C Love, Z Sun, D Jima, G Li, J Zhang, R Miles, KL Richards, CH Dunphy, ... Nature genetics 44 (12), 1321-1325, 2012 | 671 | 2012 |
| The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee E Campo, ES Jaffe, JR Cook, L Quintanilla-Martinez, SH Swerdlow, ... Blood, The Journal of the American Society of Hematology 140 (11), 1229-1253, 2022 | 650 | 2022 |
| CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma ED Hsi, R Steinle, B Balasa, S Szmania, A Draksharapu, BP Shum, ... Clinical Cancer Research 14 (9), 2775-2784, 2008 | 645 | 2008 |
| Genetic heterogeneity of diffuse large B-cell lymphoma J Zhang, V Grubor, CL Love, A Banerjee, KL Richards, PA Mieczkowski, ... Proceedings of the National Academy of Sciences 110 (4), 1398-1403, 2013 | 626 | 2013 |
| ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes ER Parrilla Castellar, ES Jaffe, JW Said, SH Swerdlow, RP Ketterling, ... Blood, The Journal of the American Society of Hematology 124 (9), 1473-1480, 2014 | 501 | 2014 |
| Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202) JL Rubenstein, ED Hsi, JL Johnson, SH Jung, MO Nakashima, B Grant, ... Journal of Clinical Oncology 31 (25), 3061, 2013 | 497 | 2013 |
| STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia A Jerez, MJ Clemente, H Makishima, H Koskela, F LeBlanc, K Peng Ng, ... Blood, The Journal of the American Society of Hematology 120 (15), 3048-3057, 2012 | 442 | 2012 |
| Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large … C Visco, Y Li, ZY Xu-Monette, RN Miranda, TM Green, A Tzankov, W Wen, ... Leukemia 26 (9), 2103-2113, 2012 | 401 | 2012 |
| Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP … ZY Xu-Monette, L Wu, C Visco, YC Tai, A Tzankov, W Liu, ... Blood, The Journal of the American Society of Hematology 120 (19), 3986-3996, 2012 | 392 | 2012 |
| Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A AM Jankowska, H Makishima, RV Tiu, H Szpurka, Y Huang, F Traina, ... Blood, The Journal of the American Society of Hematology 118 (14), 3932-3941, 2011 | 368 | 2011 |
| Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study JN Winter, EA Weller, SJ Horning, M Krajewska, D Variakojis, ... Blood 107 (11), 4207-4213, 2006 | 365 | 2006 |
| MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies GS Choudhary, S Al-Harbi, S Mazumder, BT Hill, MR Smith, J Bodo, ... Cell death & disease 6 (1), e1593-e1593, 2015 | 363 | 2015 |
| Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance/CALGB 50303 NL Bartlett, WH Wilson, SH Jung, ED Hsi, MJ Maurer, LD Pederson, ... Journal of clinical oncology 37 (21), 1790, 2019 | 353 | 2019 |
| T cell activation induces rapid tyrosine phosphorylation of a limited number of cellular substrates ED Hsi, JN Siegel, Y Minami, ET Luong, RD Klausner, LE Samelson Journal of Biological Chemistry 264 (18), 10836-10842, 1989 | 299 | 1989 |
| US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose–positron emission tomography imaging: Southwest … OW Press, H Li, H Schöder, DJ Straus, CH Moskowitz, M LeBlanc, ... Journal of Clinical Oncology 34 (17), 2020, 2016 | 296 | 2016 |
| Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation H Szpurka, R Tiu, G Murugesan, S Aboudola, ED Hsi, KS Theil, ... Blood 108 (7), 2173-2181, 2006 | 290 | 2006 |
| CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL … S Hu, ZY Xu-Monette, A Balasubramanyam, GC Manyam, C Visco, ... Blood, The Journal of the American Society of Hematology 121 (14), 2715-2724, 2013 | 279 | 2013 |
